Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie Ye

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Cancer Science|April 11, 2012
Sorting nexin 5 of a new diagnostic marker of papillary thyroid carcinoma regulates Caspase-2Shihoko Ara, Tomoki Kikuchi, Hiroshi Matsumiya, et al.
The Journal of Rheumatology|December 16, 2024
Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)Jenny Xiaoyu Li, Marie Hudson, Carrie Ye, et al.
The American Journal of Pathology|January 13, 2011
Arachidonate 5-lipoxygenase establishes adaptive humoral immunity by controlling primary B cells and their cognate T-cell helpTsutomu Nagashima, Shingo Ichimiya, Tomoki Kikuchi, et al.
ACR Open Rheumatology|February 18, 2025
Chronicity of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno-Oncology DatabaseAlexandra Ladouceur, Shahin Jamal, Alexandra Saltman, et al.
Cancer Immunology, Immunotherapy : CII|January 20, 2021
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-OncologySabrina Hoa, Linda Laaouad, Janet Roberts, et al.
The Journal of Rheumatology|September 15, 2025
Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic DiseasesCarrie Ye, Roko P A Nikolic, May Choi, et al.
Journal of Medical Internet Research|April 8, 2026
The Alberta Quality Assessment Tool: Risk of Bias (AQAT:RoB) for the Evaluation of Medical Large Language Model Question-Answer Studies: Development and Pilot ValidationCarrie Ye, Joseph Ross Mitchell, Daniel C Baumgart, et al.
Journal of Medical Internet Research|February 25, 2026
The Alberta Risk of Bias Assessment Tool (AQAT:RoB) for the Evaluation of Medical Large Language Model Question-Answer Studies: Development and Pilot ValidationCarrie Ye, Joseph Ross Mitchell, Daniel C Baumgart, et al.
The Journal of Rheumatology|September 15, 2025
Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory ArthritidesCarrie Ye, Roko P A Nikolic, May Choi, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Cancer Science|April 11, 2012
Sorting nexin 5 of a new diagnostic marker of papillary thyroid carcinoma regulates Caspase-2Shihoko Ara, Tomoki Kikuchi, Hiroshi Matsumiya, et al.
The Journal of Rheumatology|December 16, 2024
Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)Jenny Xiaoyu Li, Marie Hudson, Carrie Ye, et al.
The American Journal of Pathology|January 13, 2011
Arachidonate 5-lipoxygenase establishes adaptive humoral immunity by controlling primary B cells and their cognate T-cell helpTsutomu Nagashima, Shingo Ichimiya, Tomoki Kikuchi, et al.
ACR Open Rheumatology|February 18, 2025
Chronicity of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno-Oncology DatabaseAlexandra Ladouceur, Shahin Jamal, Alexandra Saltman, et al.
Cancer Immunology, Immunotherapy : CII|January 20, 2021
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-OncologySabrina Hoa, Linda Laaouad, Janet Roberts, et al.
The Journal of Rheumatology|September 15, 2025
Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic DiseasesCarrie Ye, Roko P A Nikolic, May Choi, et al.
Journal of Medical Internet Research|April 8, 2026
The Alberta Quality Assessment Tool: Risk of Bias (AQAT:RoB) for the Evaluation of Medical Large Language Model Question-Answer Studies: Development and Pilot ValidationCarrie Ye, Joseph Ross Mitchell, Daniel C Baumgart, et al.
Journal of Medical Internet Research|February 25, 2026
The Alberta Risk of Bias Assessment Tool (AQAT:RoB) for the Evaluation of Medical Large Language Model Question-Answer Studies: Development and Pilot ValidationCarrie Ye, Joseph Ross Mitchell, Daniel C Baumgart, et al.
The Journal of Rheumatology|September 15, 2025
Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory ArthritidesCarrie Ye, Roko P A Nikolic, May Choi, et al.
Pageof 7